First a disclaimer. This is my first public stock purchase. Losing my public investment virginity has been both exciting and painful. Also, my medical background consists of having had triple bypass surgery and back in college having dated a very cute pre-med student. The latter lasted about as long as the surgery.

With that stated I think your number 4 might come the closest. It reminds me of my college Ethics class. Who gets saved and who dies? As I understand it, and please correct, we have about 1.2M vials in inventory, which is about 600k doses, or about 300k full treatments at two doses. If accurate, or in the neighborhood, who gets to live and who dies? If the data is stat significant wouldn't they want to develop a reasonable manufacturing plan to announce with the data? Even the contracted 2021 production would not be enough and timing is an issue even with that.

Again, just a rookie here, but it seems to me the biggest problem may be what NP said sometime ago: Manufacturing, Manufacturing, and Manufacturing.

Wouldn't it be nice if I was right. <grin>